



News Release

February 9, 2026

## PreveCeutical Announces Filing of Patent for Delivery of CNS-Active Agents

**Vancouver, British Columbia: PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”)** (CSE: PREV, OTCQB: PRVCF, FSE: 18H) is pleased to announce it has filed an International (PCT) patent application on February 5, 2026, having the application no. PCT/US2026/014110, and entitled “Delivery of CNS-active therapeutic agents”.

The international patent application covers innovative methods and formulations aimed at addressing longstanding challenges in the treatment of neurological diseases and disorders. Of particular interest is Parkinson’s disease, which is a neurodegenerative condition afflicting over 10 to 12 million globally, and it is cited as the 2<sup>nd</sup> most common neurodegenerative disorder after dementia. Progressive symptoms of Parkinson’s disease include unilateral movement issues, typically presenting as a slight tremor and quiet speech in the early stages, through to severe disability that impacts eating, bathing and dressing, complemented by cognitive decline.

Depletion of the neurotransmitter dopamine in the brain is the key driver of Parkinson’s. Direct supplementation with dopamine is not currently a viable option, due to it being unable to cross the blood-brain barrier, and treatments most typically involve oral administration of the dopamine precursor, levodopa (L-dopa). As Parkinson’s is a progressive disease also impacting the health of dopaminergic neurons, their gradual decline in numbers is inevitable, reaching a threshold that renders supplementation with L-dopa ineffective.

PreveCeutical has now developed an approach for the delivery of central nervous system (CNS)-active drugs, such as dopamine, directly to the brain, and formulations that are adapted for this delivery mode. By supplying the native neurotransmitter (dopamine) directly to the brain, the Company proposes circumventing the need to administer L-dopa, dopamine agonists and other therapeutics progressively prescribed for the management of Parkinson’s across the spectrum of disease. Furthermore, this approach has the potential to offer patients in the advanced stages of Parkinson’s a safe and effective treatment option, through direct replenishment of dopamine in the brain, potentially circumventing the need for advanced/invasive treatments.

More broadly, PreveCeutical’s novel approach has the potential to address historical bottlenecks in the delivery of a range of peripherally-restricted therapeutics for CNS conditions, and it is actively exploring options to exploit these opportunities.

Commenting on the filing, PreveCeutical Chief Executive Officer Stephen Van Deventer stated, “Despite decades of research, there is still no proven clinical strategy for delivering dopamine directly to the brain. Our technology aims to change that, and we believe it represents an important step toward transforming the treatment landscape for Parkinson’s disease and other central nervous system disorders.”

The Company is not making any express or implied claims that its product and approach has the ability to manage Parkinson’s disease at this time.

Although PreveCeutical believes that any such intentions, plans, estimates, beliefs, and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs, and expectations will prove to be accurate or successful.

### **About PreveCeutical**

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit our website [www.PreveCeutical.com](http://www.PreveCeutical.com) or follow us on [Twitter](#) and [Facebook](#).

### **On behalf of the Board of Directors of PreveCeutical**

Stephen Van Deventer, Chairman and Chief Executive Officer

### **For further information, please contact:**

Stephen Van Deventer: +1 604 306 9669  
Or Investor Relations [ir@preveceutical.com](mailto:ir@preveceutical.com)

*Neither the CSE nor any Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.*

### **Forward-Looking Statements:**

*Certain information in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements in this news release include: that the Company's patent will be successfully granted by the regulators; that the Company's technology for delivering drugs directly to the brain by directly crossing the blood-brain barrier will be successful and that the Company's technology will be a treatment for Parkinson's disease or have any positive effects on those with Parkinson's disease. Forward-looking information is based on reasonable assumptions that have been made by PreveCeutical as at the date of such information and is subject to known and unknown risks, uncertainties and other factors that*

*may cause the actual results, level of activity, performance or achievements of PreveCeutical to be materially different from those expressed or implied by such forward-looking information, including but not limited to: the risk of PreveCeutical not obtaining the patent applied for; the risk that the technology which is the subject of the patent not successfully working for the administration of drugs directly through the blood-brain barrier; the risk that the Company will not have access to the necessary capital to operate its business; the accuracy of PreveCeutical's projections and estimates; interest and exchange rates; competition; share price fluctuations; actual results of activities; government regulation; political or economic developments; environmental risks; insurance risks; capital expenditures; operating or technical difficulties in connection with research and development activities; personnel relations; changes and volatility in project parameters as plans continue to be refined; the inherent uncertainties regarding cost estimates, financing, cost overruns, availability of materials and equipment, timeliness of government approvals, taxation, political risk and related economic risk; global financial conditions; the market price of PreveCeutical's securities; ability to access capital; changes in interest rates; liabilities and risks inherent in research and development operations; the potential influence of or reliance upon PreveCeutical's business partners, and the adequacy of insurance coverage. Forward-looking information is based on certain assumptions that PreveCeutical believes is reasonable, including that the technology which is the subject of the patent is successful in the administration of drugs directly through the blood-brain barrier; sufficient working capital will be available for operation of the business; that the general business and economic conditions will not change in a material adverse manner, that financing will be available if and when needed on reasonable terms and that PreveCeutical will not experience any material labour dispute, accident, or failure of plant or equipment, as well as the risks and uncertainties which are more fully described in the Company's annual and quarterly management's discussion and analysis and in other filings made by the Company with Canadian securities regulatory authorities under the Company's SEDAR+ profile. Although PreveCeutical has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. PreveCeutical does not undertake to update any forward-looking information contained herein or that is incorporated by reference herein, except in accordance with applicable securities laws.*